Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Dalcetrapib is a modulator of cholesteryl ester transfer protein (CETP) activity developed to raise levels of high-density lipoprotein cholesterol (HDL-C) with the goal of further reduction of cardiovascular events additive to standard of care alone. In clinical studies, dalcetrapib has been shown to effectively increase levels of HDL-C with no significant safety concerns.
Objective: The primary objective was to investigate the safety of single ascending and multiple ascending doses of dalcetrapib at doses markedly greater than that intended therapeutically (600 mg/day). Secondary objectives were to investigate the pharmacokinetics/pharmacodynamics and dose proportionality of dalcetrapib.
Study Design: Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose phase I study. Healthy males (age 18–65 years, body mass index 18–?2) were randomized to four of five dalcetrapib doses (2100,2700, 3300, 3900 or 4500 mg) or placebo, with ≥10 days washout between doses (n= 15, single ascending doses) or to dalcetrapib (1800, 2100, 3000 or 3900 mg once daily) or placebo for 7 days (four cohorts, each n= 10, randomization 8:2, multiple ascending doses).
Main Outcome Measure: Tolerability and safety were assessed by monitoring adverse events (AEs), laboratory parameters, vital signs and 12-lead ECG recordings. Primary pharmacokinetic assessments were area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC∞) and maximum observed plasma concentration (Cmax) [single doses] and AUC from time zero to 24 hours (AUC24) and Cmax (multiple doses). Pharmacodynamic assessments included CETP activity and lipids (multiple dosing only).
Results: Exposure increased with dose but was less than proportional to increasing dose after single dosing, although deviation from dose proportionality could not be demonstrated for Cmax. Dose proportionality was consistent following multiple doses. Steady state was modelled to have been reached by approximately 4 days, with little to no accumulation. CETP activity reduction was dose dependent (maximum −55% after 3900 mg; placebo −2.6%) at 6 hours post-dose on day 1, while HDL-C increased by 12–19% (placebo −13%) on day 8 following treatment with 1800−3900 mg/day for 7 days. All AEs were mild or moderate in intensity and there were no serious AEs, deaths or withdrawals due to AEs. No clinically relevant effects on laboratory parameters, cardiac parameters or vital signs were noted.
Conclusion: Single-dose dalcetrapib up to 4500 mg and multiple doses up to 3900 mg were generally safe and well tolerated.
- Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005 Jan 18; 45(2): 185–97 CrossRef
- Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 Sept 27; 357(13): 1301–10 CrossRef
- Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 May; 62(5): 707–14 CrossRef
- Assmann G, Schulte H, von Eckardstein A, et al. Highdensity lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 Jul; 124(Suppl.): S11–20 CrossRef
- Barter PJ, Brewer Jr HB, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003 Feb 1; 23(2): 160–7 CrossRef
- Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 Nov 22; 357(21): 2109–22 CrossRef
- Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 Jul 14; 370(9582): 153–60 CrossRef
- Kastelein JJ, vanLeuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356(16): 1620–30 CrossRef
- Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 Mar 29; 356(13): 1304–16 CrossRef
- Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-ß-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010 Dec; 51(12): 3443–54 CrossRef
- de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose response study. Circulation 2002 May 7; 105(18): 2159–65 CrossRef
- Kuivenhoven JA, deGrooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005 May 1; 95(9): 1085–8 CrossRef
- Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009 Jul 1; 104(1): 82–91 CrossRef
- Kuhlmann O, Heinig K. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica. In press
- International Conference on Harmonisation. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Oct. 2005 [online]. Available from URL: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm129335.htm [Accessed 2009 Jun 1]
- Data on file, Roche. Report No. 1020407. Basel: July 2006
- Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 2009 Mar; 31(3): 586–99 CrossRef
- Derks M, Abt M, Mwangi A, et al. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010 Jun 3; 66: 775–83 CrossRef
- Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010 Jan; 31(4): 480–8 CrossRef
- Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec; 158(6): 896–901 CrossRef
- Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009 Apr; 25(4): 891–902 CrossRef
- Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010 Oct; 50(10): 1188–201 CrossRef
- Derks M, Abt M, Parr G, et al. No clinically relevant drug-drug interactions when dalcetrapib is coadministered with atorvastatin. Expert Opin Investig Drugs 2010 Oct; 19(10): 1135–45 CrossRef
- Derks M, Abt M, Phelan M. Lack of clinically relevant drug-drug interactions when dalcetrapib is coadministered with ezetimibe. Br J Clin Pharmacol 2010 Dec; 70(6): 825–33 CrossRef
- Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects
Clinical Drug Investigation
Volume 31, Issue 5 , pp 325-335
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors